Related Experiment Videos
Muscle relaxants in renal disease
1University Department of Anaesthesia, Royal Liverpool University Hospital, UK.
Acta Anaesthesiologica Scandinavica. Supplementum
|January 1, 1994
Summary
Neuromuscular blocking drugs for chronic renal failure patients are reviewed. Atracurium and vecuronium offer benefits over older agents, with new drugs showing promise.
Area of Science:
- Anesthesiology
- Nephrology
- Pharmacology
Background:
- Chronic renal failure (CRF) impacts drug metabolism and excretion.
- Anesthetic management in CRF patients requires careful drug selection.
- Neuromuscular blocking drugs (NMBDs) are commonly used in anesthesia.
Purpose of the Study:
- To discuss the use of NMBDs in patients with chronic renal failure.
- To compare the advantages and disadvantages of different NMBDs in this population.
Main Methods:
- Review of existing literature on NMBDs in CRF.
- Analysis of pharmacokinetic and pharmacodynamic properties of NMBDs.
- Evaluation of clinical outcomes associated with NMBD use in CRF.
Main Results:
- Older non-depolarizing NMBDs (tubocurarine, alcuronium, pancuronium) have disadvantages in CRF.
- Atracurium and vecuronium offer significant benefits due to their Hofmann elimination and hepatic metabolism, respectively.
- Newer agents like pipecuronium, mivacurium, doxacurium, and rocuronium show potential but require further investigation.
Conclusions:
- Atracurium and vecuronium are preferred NMBDs for patients with chronic renal failure.
- Careful selection of NMBDs is crucial for safe anesthesia in CRF patients.
- Ongoing research into newer NMBDs may provide further options for this patient group.